Journal
LEUKEMIA & LYMPHOMA
Volume 42, Issue 4, Pages 569-576Publisher
HARWOOD ACAD PUBL GMBH
DOI: 10.3109/10428190109099316
Keywords
philadelphia positive; B-ALL; uncommitted progenitor cell; BCR-ABLp(190)
Categories
Funding
- NCI NIH HHS [1 R01 CA79955-01] Funding Source: Medline
Ask authors/readers for more resources
BCR-ABL is a chimeric oncogene generated by translocation of sequences from the c-ABLgene on chromosome 9 into the BCR gene on chromosome 22. Alternative chimeric proteins, BCR-ABLp(190) and BCR-ABLp(210), are produced that are characteristic of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (Ph-1-ALL) respectively. In CML, it is evident that the transformation occurs at the level of pluripotent stem cells. However, Ph-1-ALL has been thought to affect progenitor cells with lymphoid differentiation. Recently, it has been demonstrated that normal primitive cells, rather than committed progenitor cells, are the target for leukemic transformation in Ph-1-ALL. In this review, we discuss what is known about the relationship between the specific BCR-ABLp(190) oncogene, the target cell and the characteristics of the subsequent disease process it causes. We also discuss how this information may be applied to the establishment of new directions in therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available